Cargando…

A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma

The management of older patients with aggressive non-Hodgkin's lymphoma presents a challenge to the physician. Age is a poor prognostic indicator, due to reduced ability to tolerate and maintain dose-intensive chemotherapy. Generally, older patients demonstrate a lower response rate, reduced su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burton, C, Linch, D, Hoskin, P, Milligan, D, Dyer, M J S, Hancock, B, Mouncey, P, Smith, P, Qian, W, MacLennan, K, Jack, A, Webb, A, Cunningham, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216418/ https://www.ncbi.nlm.nih.gov/pubmed/16508640 http://dx.doi.org/10.1038/sj.bjc.6602975

Ejemplares similares

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO
por: Sharma, Rohini, et al.
Publicado: (2009)

A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.
por: Linch, D. C., et al.
Publicado: (1996)

Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma
por: Spicer, J, et al.
Publicado: (2004)

Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
por: Kühnl, A., et al.
Publicado: (2017)

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML
por: Harrison, C N, et al.
Publicado: (1999)

Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy.
por: Vaughan Hudson, B., et al.
Publicado: (1994)

Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI)
por: Yung, L, et al.
Publicado: (2004)

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial
por: Gleeson, M., et al.
Publicado: (2017)

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors
por: Cooke, R, et al.
Publicado: (2013)

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial
por: Hancock, B W, et al.
Publicado: (2001)

Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP
por: Doumas, Stergios, et al.
Publicado: (2013)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi
por: Gopal, Satish, et al.
Publicado: (2016)

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.
por: Swerdlow, A. J., et al.
Publicado: (1993)

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice
por: Bascuas, Thais, et al.
Publicado: (2018)

Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.
por: Leonard, R. C., et al.
Publicado: (1983)

High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas
por: Huang, Li-Wen, et al.
Publicado: (2021)

Pruebas en Laboratorio de dos cebos en trampas adhesivas para la atracción y captura de Triatoma dimidiata ( Latreille, 1811) ( Insecta: Hemiptera, Reduviidae) :
por: Vallejos Mihotek, Camilo Andrés
Publicado: (2008)

Thomas Hodgkin (The Fitzpatrick Lecture)
por: Hancock, P. E. Thompson
Publicado: (1968)

A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma
por: Swaneveld, F. H., et al.
Publicado: (2007)

Comportamiento de anastrepha ludens (LOEW), A. serpentina (widemann), A.striaba (SCHINER) Y A. obliqua (MACQUART) (DIPTERA: TEPHRITIDAE) en respuesta a diversos cebos alimenticios
por: Vazquez Vargas, Alejandro Gabriel
Publicado: (1996)

The incidence of B cell leukaemia and lymphopenia in B cell neoplasia in adults: a study using the Kiel classification of non-Hodgkin's lymphoma.
por: Cader, A., et al.
Publicado: (1983)

British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
por: Hancock, B. W., et al.
Publicado: (1991)

Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)
por: Townsend, William, et al.
Publicado: (2019)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma
por: Yang, Jing, et al.
Publicado: (2022)

ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(−2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients
por: Watts, M J, et al.
Publicado: (2000)

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy
por: Kim, Tark, et al.
Publicado: (2012)

CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
por: KÃ¶ppler, H., et al.
Publicado: (1989)

Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
por: Guidez, Stephanie, et al.
Publicado: (2019)

How Do We Meet the Supportive Care and Information Needs of Those Living With and Beyond Bladder Cancer?
por: MacLennan, Sara Jane, et al.
Publicado: (2020)

3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin’s lymphoma
por: Mihalcea, Diana, et al.
Publicado: (2020)

Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases.
por: Morton, J. E., et al.
Publicado: (1993)

FXR controls CHOP expression in steatohepatitis
por: Fuchs, Claudia D., et al.
Publicado: (2017)

Scoop and chop - A modified phaco-chop technique for pseudoexfoliation and cataract
por: Rao, Aparna, et al.
Publicado: (2020)

Comparison of power-free-chop and phaco-chop techniques for moderate nuclei
por: Yao, Lin, et al.
Publicado: (2020)

R-CHOP-Associated Graves' Hyperthyroidism
por: Mora, Natalie, et al.
Publicado: (2019)

Pooled analysis of AIDS Malignancy Consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin’s lymphoma
por: Barta, Stefan K, et al.
Publicado: (2010)

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
por: Takeyasu, Yuki, et al.
Publicado: (2017)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_57k3s17uptjpbjopesse1ov3db